BACKGROUND: The role of consolidation radiotherapy was examined for patients with diffuse large B-cell lymphoma who were treated at institutions of the National Comprehensive Cancer Network during the rituximab era. METHODS: Failure-free survival (FFS) and overall survival (OS) were analyzed in terms of patient and treatment characteristics. Potential associations were investigated with univariate and multivariate survival analysis and matched pair analysis. RESULTS: There were 841 patients, and most (710 or 84%) received 6 to 8 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); 293 (35%) received consolidation radiation therapy (RT). Failure occurred for 181 patients: 126 patients (70%) who did not receive RT and 55 patients (30%) who did. At 5 years, both OS and FFS rates were better for patients who had received RT versus those who did not (OS, 91% vs 83% [P = .01]; FFS, 83% vs 76% [P = .05]). A matched pair analysis (217 pairs matched by age, stage, International Prognostic Index [IPI] score, B symptoms, disease bulk, and response to chemotherapy) showed that the receipt of RT improved OS (hazard ratio [HR], 0.53 [P = .07]) and FFS (HR, 0.77 [P = .34]) for patients with stage III/IV disease, but too few events took place among those with stage I/II disease for meaningful comparisons (HR for OS, 0.94 [P = .89]; HR for FFS, 1.81 [P = .15]). A multivariate analysis suggested that the IPI score and the response to chemotherapy had the greatest influence on outcomes. CONCLUSIONS: There was a trend of higher OS and FFS rates for patients who had received consolidation RT after R-CHOP (especially for patients with stage III/IV disease), but the difference did not reach statistical significance.
BACKGROUND: The role of consolidation radiotherapy was examined for patients with diffuse large B-cell lymphoma who were treated at institutions of the National Comprehensive Cancer Network during the rituximab era. METHODS: Failure-free survival (FFS) and overall survival (OS) were analyzed in terms of patient and treatment characteristics. Potential associations were investigated with univariate and multivariate survival analysis and matched pair analysis. RESULTS: There were 841 patients, and most (710 or 84%) received 6 to 8 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); 293 (35%) received consolidation radiation therapy (RT). Failure occurred for 181 patients: 126 patients (70%) who did not receive RT and 55 patients (30%) who did. At 5 years, both OS and FFS rates were better for patients who had received RT versus those who did not (OS, 91% vs 83% [P = .01]; FFS, 83% vs 76% [P = .05]). A matched pair analysis (217 pairs matched by age, stage, International Prognostic Index [IPI] score, B symptoms, disease bulk, and response to chemotherapy) showed that the receipt of RT improved OS (hazard ratio [HR], 0.53 [P = .07]) and FFS (HR, 0.77 [P = .34]) for patients with stage III/IV disease, but too few events took place among those with stage I/II disease for meaningful comparisons (HR for OS, 0.94 [P = .89]; HR for FFS, 1.81 [P = .15]). A multivariate analysis suggested that the IPI score and the response to chemotherapy had the greatest influence on outcomes. CONCLUSIONS: There was a trend of higher OS and FFS rates for patients who had received consolidation RT after R-CHOP (especially for patients with stage III/IV disease), but the difference did not reach statistical significance.
Authors: Paul N Meyer; Kai Fu; Timothy C Greiner; Lynette M Smith; Jan Delabie; Randy D Gascoyne; German Ott; Andreas Rosenwald; Rita M Braziel; Elias Campo; Julie M Vose; Georg Lenz; Louis M Staudt; Wing C Chan; Dennis D Weisenburger Journal: J Clin Oncol Date: 2010-12-06 Impact factor: 44.544
Authors: Jack Phan; Ali Mazloom; L Jeffrey Medeiros; Tony G Zreik; Christine Wogan; Ferial Shihadeh; Maria Alma Rodriguez; Luis Fayad; Nathan Fowler; Valerie Reed; Patrecia Horace; Bouthaina Shbib Dabaja Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier-Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt Journal: Lancet Oncol Date: 2008-04-08 Impact factor: 41.316
Authors: Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick Journal: J Clin Oncol Date: 2004-06-21 Impact factor: 44.544
Authors: Deborah M Stephens; Hongli Li; Michael L LeBlanc; Soham D Puvvada; Daniel Persky; Jonathan W Friedberg; Sonali M Smith Journal: J Clin Oncol Date: 2016-07-05 Impact factor: 44.544
Authors: Martin D Berger; Sven Trelle; Annina E Büchi; Sabrina Jegerlehner; Codruta Ionescu; Thierry Lamy de la Chapelle; Urban Novak Journal: Haematologica Date: 2021-07-01 Impact factor: 9.941
Authors: Mi Joo Chung; Won Kyung Cho; Dongryul Oh; Keun-Yong Eom; Jin Hee Kim; Woo Chul Kim; Jong Hoon Lee Journal: J Radiat Res Date: 2019-10-23 Impact factor: 2.724
Authors: Joseph A Sparano; Jeannette Y Lee; Lawrence D Kaplan; Juan Carlos Ramos; Richard F Ambinder; William Wachsman; David Aboulafia; Ariela Noy; David H Henry; Lee Ratner; Ethel Cesarman; Amy Chadburn; Ronald Mitsuyasu Journal: Haematologica Date: 2021-03-01 Impact factor: 9.941
Authors: Musa Alzahrani; Mubarak M Al-Mansour; John Apostolidis; Ahmed Barefah; Reyad Dada; Ayman Alhejazi; Yasir Alayed; Ibraheem Motabi; Mansoor Radwi; Hani Al-Hashmi Journal: Saudi J Med Med Sci Date: 2020-08-20